Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
DVHGF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
businesswire.com
16 hours ago
businesswire.com
16 hours ago
businesswire.com
18 hours ago
businesswire.com
20 hours ago
businesswire.com
21 hours ago
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.01
vs -0.01
Q2.23
N/A
-0.01
vs -0.00
Q3.23
N/A
-0.00
vs -0.00
Q4.23
N/A
-0.00
vs -0.01
Q1.24
N/A
-0.01
vs -0.01
Q2.24
N/A
-0.00
vs -0.01
Q3.24
+221%
0.01
vs -0.00
Q4.24
N/A
-0.00
vs -0.00
Q1.25
N/A
-0.00
vs -0.01
Q2.25
N/A
-0.02
vs -0.00
Sales Growth
YoY
Current
Estimates
Q1.23
-14%
452.8K vs 523.5K
Q2.23
-44%
406.1K vs 729.1K
Q3.23
+76%
1.1M vs 612.1K
Q4.23
+210%
1.3M vs 410.4K
Q1.24
+403%
2.3M vs 452.8K
Q2.24
+1162%
5.1M vs 406.1K
Q3.24
+749%
9.1M vs 1.1M
Q4.24
+360%
5.9M vs 1.3M
Q1.25
+288%
8.8M vs 2.3M
Q2.25
+44%
7.4M vs 5.1M
Return on Equity
QoQ
Q1.23
-7%
-0.07
vs -0.08
Q2.23
-11%
-0.11
vs -0.07
Q3.23
-6%
-0.06
vs -0.11
Q4.23
-5%
-0.05
vs -0.06
Q1.24
-9%
-0.09
vs -0.05
Q2.24
-3%
-0.03
vs -0.09
Q3.24
+7%
0.07
vs -0.03
Q4.24
-2%
-0.02
vs 0.07
Q1.25
-2%
-0.02
vs -0.02
Q2.25
-54%
-0.54
vs -0.02
Institutionnal Ownership
N/A
Q3.23
NA
NA
vs NA
NA
Q4.23
NA
NA
vs NA
NA
Q1.24
NA
NA
vs NA
NA
Q2.24
NA
NA
vs NA
NA
Q3.24
NA
NA
vs NA
NA
Q4.24
NA
NA
vs NA
NA
Q1.25
NA
NA
vs NA
NA
Q2.25
NA
NA
vs NA
NA
Q3.25
NA
NA
vs NA
NA
Q4.25
NA
NA
vs NA
NA
Quote Panel
Key Metrics
Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine, a Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric or duodenal ulcers; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, it acquires drug and health product licenses; and distributes pharmaceutical products. Devonian Health Group Inc. has a strategic alliance with CannTx Life Sciences Inc. for the development of cannabinoid-based pharmaceutical drugs. The company was incorporated in 2015 and is headquartered in Québec, Canada.
OTC
Unprofitable
Unprofitable
Relative Strenght
Volume Buzz
6310%
Earning Acce
No
Dist 52w H.
61%Relative Strength
DVHGF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|